Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Scilex Holding Company Common Stock

SCLX

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Last trade $0.698
Day change -$0.552 (-44.16%)
Day range $0.581 – $1.26
Volume 553,638
Market cap $9M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$8.79M
Price / earnings
—
Price / book
-0.03×
Price / sales
0.28×
EV / sales
2.89×
EV / EBITDA
-0.33×

Profitability

Earnings per share
-$63.73
Return on assets
-176.82%
Return on equity
145.41%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.27×
Current ratio
0.07×
Quick ratio
0.06×
Cash ratio
0×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$17.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SCLX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$7.64M$8.61M$4.79M$10.56M$9.9M$5M$14.9M$14.44M
Cost of revenue$3.68M$4.45M$2.61M$3.33M$3.27M$1.38M$4.69M$3.77M
Gross profit$3.97M$4.17M$2.18M$7.23M$6.62M$3.62M$10.21M$10.67M
Selling, general and administrative$27.96M$31.03M$30.16M$188.82M$19.84M$28.06M$35.41M$29.73M
Research and development$3.34M$3.21M$8.17M$3.9M$6.19M$2.46M$2.18M$2.35M
Total operating expenses$33.39M$36.34M$113.27M$193.74M$27.13M$31.52M$38.59M$30.59M
Operating income-$29.42M-$32.17M-$111.09M-$186.51M-$20.51M-$27.9M-$28.38M-$19.92M
Interest expense-$6.1M-$3.78M-$3.5M-$2.8M-$2.68M-$2.48M-$285K-$576K
Income before taxes-$114.98M-$45.65M-$46.1M-$257.82M-$44.03M-$26.08M-$6.46M-$4.39M
Income taxes$7K$0$6K$1K$19K$0-$1K$0
Net income-$114.99M-$45.65M-$46.11M-$257.82M-$44.05M-$26.08M-$6.46M-$4.39M
Net income attributable to common shareholders-$114.73M-$43.27M-$33.11M-$257.23M-$86.06M-$26.08M-$6.46M-$4.39M
EBITDA-$26.58M-$29.3M-$35.9M-$185.49M-$19.4M-$26.9M-$27.37M-$21.41M
Basic earnings per share-$16.65-$6.28-$3.53-$22.17-$7.42-$2.26-$0.26-$0.58
Diluted earnings per share-$16.65-$6.28-$3.53-$22.17-$7.42-$2.26-$0.26-$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million strategic investment at $15 per share (approximately 6.67 million shares). The investment will support Scilex's growth initiatives including product development, commercialization, acquisitions, and strategic partnerships. The deal remains subject to due diligence, definitive agreements, board and stockholder approvals, and regulatory clearances.

Benzinga

Scilex (SCLX) Stock Jumps After Dream Bowl Meme Coin Listing Update: Why Is It Moving?

Scilex Holding Company shares surged 18.79% after announcing that its Dream Bowl I Meme Coin tokens will begin trading on Biconomy Exchange as early as June 23. The listing is expected to improve liquidity and enable broader distribution for eligible token holders. Scilex is a biotech company focused on non-opioid pain management products.

Benzinga

Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Scilex Holding Company announced that its board has set June 15, 2026 as the payment date for a dividend of Semnur Pharmaceuticals common stock to Scilex shareholders. The company plans to distribute approximately 14.0 million shares of Semnur (out of 186 million owned) on a 1:1 basis for each Scilex share held as of the June 1, 2026 record date. The dividend is subject to board revocation if there are material changes to solvency or surplus analysis.

Benzinga

Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026

Scilex Holding Company's board approved a dividend distribution of Semnur Pharmaceuticals common stock to its shareholders, with a record date of June 1, 2026. Scilex will distribute approximately 10.7 million shares of its ~186 million Semnur holdings to eligible equity holders at a 1:1 ratio. The payment date will be determined by subsequent board resolutions within 60 days of the record date, though the board retains the right to change the record date or revoke the dividend.

GlobeNewswire Inc.

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

Scilex Holding Company announced that its subsidiaries ACEA Therapeutics and ACEA Pharma entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited for $1 billion in newly-issued shares. Upon closing, Phoenix will be renamed ACEA Pharma and listed on Nasdaq, with ACEA Thera retaining approximately 82% ownership. The transaction is expected to close by end of Q2 2026, subject to regulatory and stock exchange approvals.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 15, 20251-for-35reverse split
May 7, 20101-for-10reverse split